Distinctions in Agonist and Antagonist Specificity Conferred by Anionic Residues of the Nicotinic Acetylcholine Receptor*

Hitoshi Osaka, Naoya SugiyamaDagger , and Palmer Taylor§

From the Department of Pharmacology 0636, University of California, San Diego, La Jolla, California 92093

    ABSTRACT
Top
Abstract
Introduction
Procedures
Results
Discussion
References

Two anionic residues in the nicotinic acetylcholine receptor, Asp-152 in the alpha -subunit and Asp-174 in the gamma -subunit or the corresponding Asp-180 in the delta -subunit, are presumed to reside near the two agonist binding sites at the alpha gamma and alpha delta subunit interfaces of the receptor and have been implicated in electrostatic attraction of cationic ligands. Through site-directed mutagenesis and analysis of state changes in the receptor elicited by agonists, we have distinguished the roles of anionic residues in conferring ligand specificity and ligand-induced state changes. alpha Asp-152 affects agonist and antagonist affinity similarly, whereas gamma Asp-174 and delta Asp-180 primarily affect agonist affinity. Combining charge neutralization on the alpha  subunit with that on the gamma  and delta  subunits shows an additivity in free energy changes for carbamylcholine and d-tubocurarine, suggesting independent contributions of these residues to stabilizing the bound ligands. Since both aromatic and anionic residues stabilize cationic ligands, we substituted tyrosines (Y) for the aspartyl residues. While the substitution, alpha D152Y, reduced the affinities for agonists and antagonists, the gamma D174Y/delta D180Y mutations reduced the affinity for agonist binding, but surprisingly enhanced the affinity for d-tubocurarine. To ascertain whether selective changes in agonist binding stem from the capacity of agonists to form the desensitized state of the receptor, carbamylcholine binding was measured in the presence of an allosteric inhibitor, proadifen. Mutant nAChRs carrying alpha D152Q or gamma D174N/delta D180N show similar reductions in dissociation constants for the desensitized compared with activable receptor state and a similar proadifen concentration dependence. Hence, these mutations influence ligand recognition rather than the capacity of the receptor to desensitize. By contrast, the alpha D200Q mutation diminishes the ratio of dissociation constants for two states and requires higher proadifen concentrations to induce desensitization. Thus, the contributions of alpha Asp-152, gamma /delta Asp-174/180, and alpha Asp-200 in stabilizing ligand binding can be distinguished by the interactions between agonists and allosteric inhibitors.

    INTRODUCTION
Top
Abstract
Introduction
Procedures
Results
Discussion
References

The nicotinic acetylcholine receptor (nAChR)1 in muscle is a pentamer composed of four homologous subunits present in a stoichiometry alpha 2beta gamma delta and arranged to surround a central channel (1-3). Simultaneous occupation of agonist at the two binding sites that reside at the interfaces of the alpha gamma and alpha delta subunits activates the nAChR by increasing the probability of channel opening. Continued exposure to agonist shifts the receptor into the desensitized state characterized by a greater than two orders of magnitude increase in agonist affinity and by a closed channel.

The extracellular domain in each subunit is formed principally from the amino-terminal 210 amino acids; this domain is followed by four transmembrane spanning regions. Since only a small segment between membrane spans 2 and 3, and the very carboxyl terminus of ~8 residues reside at the extracellular face, residues within the amino-terminal 210 amino acids should largely contribute to the agonist binding site. Three segments of the alpha -subunit, residues surrounding Tyr-93, the regions between residues 149 and 153 and between residues 180 to 200, have been shown by chemical labeling and site-directed mutagenesis to contribute to agonist binding (2, 4). Four segments on the opposing subunit interface of the gamma  and delta  subunits (identified by residues 34, 55-59, 111-119, and 172-174 on the gamma  subunit and corresponding residues on the delta  subunit) present surfaces which also appear to contribute to ligand binding (5-12). A model of the extracellular portion of the nAChR based on sequence identity with proteins of known structure and on identification of interacting residues details the known information on the extracellular domain of the receptor (13).

Long range electrostatic attractive forces and stabilization of paired charges through Coulombic interactions have long been known to control binding of charged ligands to proteins. More recently, the importance of interaction between quaternary ammonium moieties and aromatic side chains became evident through studies of model binding sites (14) and crystallographic studies of proteins that associate with quaternary ammonium ligands (15, 16).

Charged residues involved in ligand binding on the gamma  and delta  subunits of the nAChR have been identified by chemical cross linking (17, 18) and site-directed mutagenesis (7, 19). Residue proximity revealed from cross-linking and the reduction in agonist affinity associated with charge removal point to gamma Asp-174 and delta Asp-180 as critical residues. Our search for anionic residues in alpha -subunit identified alpha Asp-152 to be at the alpha gamma and alpha delta subunit interfaces, where it affects the binding of agonists and competitive alkaloid antagonists as well as subunit assembly (20). Since alpha Asp-152 and gamma Asp-174/delta Asp-180 are critical to ligand binding, yet differentially affect agonist and antagonist binding, herein we examine the role of these residues in conferring specificity and affecting state changes in the receptor. These residues are compared with other anionic residues critically positioned in the extracellular region of the receptor.

    EXPERIMENTAL PROCEDURES
Top
Abstract
Introduction
Procedures
Results
Discussion
References

Materials-- Carbamylcholine, suberyldicholine, decamethonium, and d-tubocurarine were purchased from Sigma. Dimethyl-d-tubocurarine was obtained from Lilly. 125I-alpha -Bungarotoxin (specific activity ~16 µCi/µg) was a product of NEN Life Science Products.

Site-directed Mutagenesis-- cDNAs encoding mouse nAChR subunits were subcloned into a cytomegalovirus-based expression vector, pRBG4. Single-stranded cDNAs were prepared as described previously (20). All mutations were introduced using single-stranded templates. After the mutagenesis reaction, restriction fragments containing the mutated site were subcloned into the original pBRG4 plasmid. Confirmation of the mutations and the absence of spontaneous mutations in the polymerase generated segment were established by dideoxy sequencing.

Cell Transfection-- cDNAs encoding the wild type and mutant subunits were transfected into human embryonic kidney (HEK-293) cells using Ca3(PO4)2 in the ratios of alpha  (15 µg)/beta (7.5 µg)/gamma (7.5 µg)/delta (7.5 µg) and alpha  (15 µg)/beta (7.5 µg)/gamma or delta  (15 µg).

Ligand Binding Measurements-- Cells were harvested in phosphate-buffered saline, pH 7.4, containing 5 mM EDTA, 2-3 days after transfection. They were briefly centrifuged, resuspended in potassium-Ringer's buffer, and divided into aliquots for binding assays. Specified concentrations of agonists, antagonists, and proadifen were added to the samples 20 min prior to initiating the rate of association assay with 125I-alpha -bungarotoxin. Dissociation constants of the ligands were determined from their competition with the initial rate of 125I-alpha -bungarotoxin association (21, 22).

    RESULTS
Top
Abstract
Introduction
Procedures
Results
Discussion
References

Influence of nAChR alpha  Subunit Mutations at Positions 99, 152, 180, and 200 on Ligand Binding-- Candidate anionic residues were selected in three segments of the extracellular domain of the alpha  subunit known to affect ligand binding (Table IA). In segment A (amino acids 88-99), aspartate 99 was mutated to asparagine. In segment B (amino acids 144-154), aspartate 152 was mutated to glutamine. Glutamine substitution precludes insertion of a glycosylation signal. In segment C (amino acids 180-200), two anionic residues glutamate 180 and aspartate 200 were mutated into asparagine and glutamine, respectively.

                              
View this table:
[in this window]
[in a new window]
 
Table I
A, Aligned amino acid sequences of three main ligand binding segments in the alpha  subunit of the nicotinic acetylcholine receptor and B, four segments conferring ligand specificity found in the gamma /delta subunits
Mutations studied are denoted by arrows. Conserved residues are marked with asterisks. Residues detected by affinity labeling are underlined. Residues replaced by mutagenesis in referenced studies are shown in bold type.

Fig. 1A shows the effect of charge neutralization of these anionic side chains. Both the alpha D152Q and alpha D200Q mutations shift the binding curves to more than 10-fold higher agonist concentrations, whereas alpha D99N and alpha E180N mutations produce only slight shifts in concentration dependence and a loss of positive cooperativity for the agonists (Table II). For the antagonist d-tubocurarine, the alpha D152Q mutation produces a reduction of affinity similar to that seen for the agonist (Fig. 1B) (20). In contrast, the alpha D200Q mutation showed only a small influence on d-tubocurarine binding (Fig. 1B, Table II). This was also true for the alpha D99N and alpha E180N mutations.


View larger version (25K):
[in this window]
[in a new window]
 
Fig. 1.   Agonist and antagonist inhibition of the initial rate of 125I-alpha -bungarotoxin binding to cell surface nAChRs after transfection of HEK cells. Panels A and B, transfection with cDNAs encoding wild type (open circle ) and mutant alpha  subunits, alpha D99N (black-triangle), alpha D152Q (black-down-triangle ), alpha E180N (black-diamond ), alpha D200Q (black-square), along with beta , gamma , and delta  subunit cDNAs. Panels C and D, transfection with cDNAs encoding wild type alpha  (open circle ), alpha D152Q (bullet ), gamma D174N/delta D180N (black-square), alpha D152Q and gamma D174N/delta D180N (square ) along with the complementary alpha , beta , gamma , and delta  cDNAs to achieve a pentameric receptor of stoichiometry alpha 2beta gamma delta . kobs/kmax is the ratio of initial rates for 125I-alpha -bungarotoxin binding in the presence and absence of the respective ligands (19). The lines represent least squares fits of the Hill equation to the data with the fitted dissociation constants and Hill coefficients given in Table I (20).

                              
View this table:
[in this window]
[in a new window]
 
Table II
The influence of anionic residue mutations in the alpha , gamma , and delta  subunits on carbamylcholine and d-tubocurarine dissociation constants
Dissociation constants were calculated from competition with the initial rate of the 125I-alpha -bungarotoxin binding. Receptor was expressed as alpha 2beta gamma delta , alpha 2beta gamma 2, or alpha 2beta delta 2 by transfection of the 4 or 3 respective sets of subunits. Kequil is an overall dissociation constant for carbamylcholine at equilibrium. Kd1 and Kd2 are dissociation constants for the alpha gamma and alpha delta sites for d-tubocurarine. The ratios of dissociation constants of mutant (mt) to wild type (wt) were calculated using an average or mean value of at least two measurements involving separate transfections. Delta Delta G is a change of free energy of binding associated with the mutations.

Influence of gamma D174N/delta D180N Mutations on Ligand Binding-- gamma Asp-174 and delta Asp-180 are situated in the most carboxyl-terminal position of the four segments in the gamma  and delta  subunits known to contribute to ligand binding (Table IB). After cotransfection of alpha , beta , gamma , and delta  subunits carrying the gamma D174N/delta D180N mutations, the binding curve for the agonist carbamylcholine shifts over two orders of magnitude to higher concentration (Fig. 1C), whereas less than a 10-fold shift is seen for the antagonist d-tubocurarine (Fig. 1D). To distinguish between the two binding sites, subunits containing gamma D174N or delta D180N were expressed as pentamers of either alpha 2beta gamma 2 or alpha 2beta delta 2 subunit composition on the cell surface by transfection of the requisite three cDNAs; these subunit arrangements possess apparently equivalent subunit interfaces for binding (alpha 2beta gamma 2 with two alpha -gamma sites, alpha 2beta delta 2 with two alpha -delta sites). A reduction in agonist affinity that is greater than those for antagonists is again evident with these unnatural subunit compositions (Fig. 2). The loss of cooperativity on agonist binding for alpha 2beta delta 2 pentameric receptor was also evident in previous studies (23), and likely reflects the diminished capacity of this subunit combination to elicit state transitions in response to agonists. Binding of d-tubocurarine is largely unaltered by these mutations with the alpha 2beta gamma 2 and alpha 2beta delta 2 subunit combinations. As expected for a pentamer containing two equivalent sites, the respective Hill coefficients also approach 1.0. 


View larger version (19K):
[in this window]
[in a new window]
 
Fig. 2.   Agonist and antagonist inhibition of binding of 125I-alpha -bungarotoxin to cell surface nAChRs expressed as alpha 2beta gamma 2 (panels A and B) or alpha 2beta delta 2 (panels C and D). Open circles represent wild type and filled circles represent mutant receptor; gamma D174N in panels A and B, and delta D180N in panels C and D. The analysis of data is similar to Fig. 1.

Ligand Specificity of alpha D152Q and gamma D174N/delta D180N Receptor Mutations-- The bis-quaternary agonist, suberyldicholine, shows a reduction in affinity similar to carbamylcholine for the charge neutralization mutations in the alpha  and the gamma /delta subunits, 10-fold for the alpha D152Q mutation and about 100-fold for the gamma D174N or the delta D180N mutation (Table III). Thus, mono- and bis-quaternary agonists are not differentially affected by these mutations. For bis-quaternary antagonist, dimethyl d-tubocurarine, the alpha D152Q mutation showed over a 10-fold reduction in affinity, whereas the gamma D174N or the delta D180N mutation showed only a 3-4-fold reduction; values similar to d-tubocurarine, which contains single cationic tertiary and quaternary moieties. For the bis-quaternary partial agonist, decamethonium, the loss of affinity with the mutations falls between d-tubocurarine and suberyldicholine, but somewhat closer to the antagonist (Table III).

                              
View this table:
[in this window]
[in a new window]
 
Table III
The effect of mutations, alpha D152Q, gamma D174N/delta D180N, and gamma D174Y/delta D180Y on the dissociation constants of a bisquaternary agonist, partial agonist, and antagonist
Dissociation constants were calculated as Table I. Receptors were expressed as alpha 2beta gamma delta on the cell surface.

Combining the Mutations of alpha D152Q and gamma D174N/delta D180N-- Upon expression of receptor containing charge neutralization mutations on both the alpha  and the gamma /delta subunits, the change of free energy (Delta Delta G), between the double subunit mutant combining alpha D152Q with gamma D174N/delta D180N and wild-type receptor for carbamylcholine is in close accord with the sum of Delta Delta G calculated from separate mutations on the individual subunits contained in the pentameric receptor (Fig. 1C; Table II). For d-tubocurarine, Delta Delta G between the wild-type receptor and the receptor with combined alpha  and gamma /delta substitutions is also in close accord with the sum of Delta Delta G values calculated for two respective receptors with individual substitutions in the two subunits (Fig. 1D; Table II). These results suggest that the charged residues, alpha D152Q and gamma D174N/delta D180N, confer independent, noninteracting electrostatic contributions to the binding site.

Influence of the alpha D152Q and gamma D174N/delta D180N on Receptor Desensitization-- The selectivity of the gamma D174N/delta D180N mutations for agonist, but not antagonist, affinity might be a consequence of these residue positions affecting the characteristic state transitions associated with the binding of agonists, but not antagonists. When agonists are allowed to equilibrate the receptor, the overall equilibrium constant (Kequil) reflects binding to at least three discrete receptor states: activable, active (open channel), and desensitized. The last state exhibits the highest affinity for agonists, and allosteric ligands such as local anesthetics promote a shift in the equilibria between states so that the receptor resides primarily in the desensitized state (24-30). At saturation with local anesthetics, such as proadifen (27), the apparent dissociation constant for carbamylcholine is equivalent to that for the desensitized state (KR').

We examined the possibility that a diminished capacity for desensitization was responsible for the apparent reduction of agonist affinity associated with the charge neutralization on the receptor. Fig. 3 shows binding profiles for the agonist carbamylcholine at various concentrations of a local anesthetic, proadifen. Upon increasing the concentration of proadifen, the binding curves shift to toward lower concentrations of carbamylcholine. The degree of enhancement of affinity by proadifen can be monitored from the shift in the family of carbamylcholine binding curves. In both wild type and two mutant receptors (alpha D152Q and gamma D174N/delta D180N), 10 µM proadifen is nearly sufficient for saturation (Fig. 3, panels A-C).


View larger version (19K):
[in this window]
[in a new window]
 
Fig. 3.   Carbamylcholine inhibition of 125I-alpha -bungarotoxin binding to surface membrane nAChRs in the presence of various concentrations of proadifen. Panel A, wild type receptor alpha 2beta gamma delta ; panel B, (alpha D152Q)2beta gamma delta ; panel C, alpha 2beta gamma D174N/delta D180N; panel D, (alpha D200Q)2beta gamma delta ; and panel E, alpha 2beta gamma D174Y/delta D180Y. Proadifen concentrations are 1 µM (black-triangle), 10 µM (black-down-triangle ), 30 µM (black-diamond ), 90 µM (black-square), and 200 µM (bullet ), no proadifen (open circle ). The analysis of data is similar to Fig. 1.

Similar degrees of shift of carbamylcholine affinity in the presence and absence of proadifen are observed for the wild type (Kequil/KR' = 120), alpha D152Q (Kequil/KR' = 88) and gamma D174N/delta D180N (Kequil/KR' = 130) mutant receptors (Fig. 4). Therefore, the alpha D152Q and the gamma D174N/delta D180N mutants retain their capacity for desensitization or conversion to a high affinity state, and the large influence of the charge neutralization mutation on agonist binding does not arise from a compromised capacity of the mutant receptor to desensitize. Furthermore, the concentration dependence for proadifen in effecting the increase in carbamylcholine affinity for the alpha D152Q and the gamma D174N/delta D180N mutant receptors are superimposable with that found for wild-type receptor (Fig. 4, panels A-C).


View larger version (11K):
[in this window]
[in a new window]
 
Fig. 4.   Ratios of carbamylcholine dissociation constants in the absence and presence of proadifen. Panel A, wild type receptor alpha 2beta gamma delta ; panel B, (alpha D152Q)2beta gamma delta ; panel C, alpha 2beta gamma D174N/delta D180N; panel D, (alpha D200Q)2beta gamma delta ; and panel E, alpha 2beta gamma D174Y/delta D180Y. Data are derived from the family of curves similar to those shown in Fig. 3.

Influence of alpha D200Q Mutation on Receptor Desensitization-- A previous study of the permeability response of the mouse nAChR expressed from mRNAs encoding the individual subunits when injected into Xenopus oocytes showed a only minor influence of alpha D200N on the concentration dependence for activation and functional antagonism (8). Our study shows a larger influence of this mutation on carbamylcholine binding at equilibrium, over one order of magnitude reduction in affinity (Fig. 1). d-Tubocurarine affinity is less affected by this mutation (Fig. 1). Exposure of the ligand to the receptor prior to assay allows all of the receptor states to equilibrate in the binding measurement, whereas the concentration dependence of the permeability response does not reflect the fraction of receptor in the desensitized state. Therefore, transitions to the desensitized states may explain the difference between the two studies.

For the alpha D200Q mutant, the ratio of dissociation constants (Kequil/KR' = 22) (Figs. 3 and Fig. 4, panel D) is significantly reduced compared with wild-type and the other receptor mutations with charge neutralization in the alpha  or gamma /delta subunits. The proadifen concentration dependence also increases where half-maximal conversion occurs at 61 µM, a value more than 10-fold higher than for wild type (Figs. 3D and 4D). These data indicate that the capacity for desensitization and for conversion to the high affinity state contributes to the overall dissociation constant measured at equilibrium and may well account for the interesting differences seen for this mutant between the previous measurements of permeability (8) and our binding studies.

Substitutions of Tyrosine for the Anionic Residues in the alpha  and gamma /delta Subunits-- Since both anionic and aromatic residues are known to stabilize complexes of quaternary ligands and their binding sites, we determined whether substitutions of tyrosine for the charged residues would still result in a binding site that accommodates the bound agonist and antagonist. Although capacity for surface expression of receptor with the alpha D152Y mutation is about 30% of that of its alpha D152Q mutation, ligand binding affinities for carbamylcholine and d-tubocurarine are similar to those seen with alpha D152Q (Fig. 5). The gamma D174Y/delta D180Y mutation also results in a loss of affinity for carbamylcholine, but leads to an enhanced affinity for d-tubocurarine (Fig. 5; Table II). This increase in affinity is also seen for structurally related bisquaternary antagonist, dimethyl d-tubocurarine (Table III).


View larger version (20K):
[in this window]
[in a new window]
 
Fig. 5.   Ligand inhibition of the initial rate of binding of 125I-alpha -bungarotoxin to cell surface nAChRs. Wild type (open circle ), alpha D152Q (black-diamond ), alpha D152Y (diamond ), gamma D174N/delta D180N (black-square), and gamma D174Y/delta D180Y (square ) mutant receptors. All nAChRs are expressed as alpha 2beta gamma delta and carry wild type sequences at the nonmutated positions. The analysis of data is similar to Fig. 1.

The Influence of Proadifen on the gamma D174Y/delta D180Y Mutant Receptor-- The profile of binding curves for carbamylcholine in the presence of proadifen differs between the gamma D174Y/delta D180Y and gamma D174N/delta D180N (Fig. 3, panels E and C). Proadifen at 1 µM does not affect carbamylcholine binding and only at 10 µM gives a shift in the binding profile comparable to that found for wild type and the gamma /delta D174/D180N mutant receptors at 1 µM proadifen. The proadifen concentration which gives a half-maximal shift in carbamylcholine affinities is nearly an order of magnitude greater than the wild-type receptor (Fig. 3, A and E). Moreover, the magnitude of proadifen elicited shift in carbamylcholine binding to higher affinity for the gamma D174Y/delta D180Y mutant is approximately 4 times smaller than that found for wild-type receptor.

    DISCUSSION
Top
Abstract
Introduction
Procedures
Results
Discussion
References

Hydrophobic and Electrostatic Forces Affecting Ligand-nAChR Complexes-- The forces involved in stabilization of quaternary ammonium complexes with macromolecules have been studied for nearly a half-century and reveal both hydrophobic and electrostatic contributions to their stabilization (31). Electrostatic forces have been quantified by ionic strength masking of rates of association enhanced by electrostatic attraction or slowed by repulsion. Apart from long range forces generated from an electrostatic dipole in the binding site, charge may serve to stabilize particular orientations of the bound ligand or to entrap the ligand in the target site (16, 32). Recent studies with model compounds and crystallographic studies of complexes with quaternary ligands also show the importance of aromatic residues in interacting with cations through an ion quadripole interaction (14-16). Perspectives on the importance of charged versus aromatic amino acid side chains depend in large part on the measurement technique. Photolytic labeling of the nAChR reveals the involvement of proximal aromatic residues in binding since those very residues are susceptible to photolysis (33). The crystal structures of the phosphorylcholine antibody (15) and acetylcholinesterase (16) show their binding sites for quaternary ligands to be heavily surrounded with aromatic residues. Nevertheless strategically placed charges, where longer range electrostatic forces (1/r in coulombic interactions versus 1/r6 and 1/r3 for hydrophobic dispersion forces and ion-quadripole interactions), appear important for stabilization of these complexes.

Formation of site-specific mutants of the cholinesterase have clearly delineated the importance of both aromatic and charged residues on the enzyme in stabilizing quaternary ions (34, 35). With the nAChR, chemical cross-linking (17, 18) and subsequently mutagenesis studies have pointed to the cationic residue, on the gamma  subunit Asp-174 (7), and the corresponding residue Asp-180 (19), on the delta  subunit, to lie within 10 Å of cysteine 192 or 193 of the alpha  subunit and to be critical for the binding of agonists.

Martin and Karlin (23) have introduced several mutations at the gamma Asp-174 and delta Asp-180 positions and have analyzed the electrostatic and steric influences of these residues on ligand binding and activation. Their studies, conducted by co-injection of mouse subunit receptors into Xenopus oocytes, also revealed that these mutations primarily decreased agonist, rather than antagonist affinity (19, 23), and that the loss of affinity was observed equivalently in receptor states involving activation and desensitization (23). Other studies analyzing the electrostatic potential by introduction of charged methanethiosulfonates at cysteines are consistent with an agonist binding site containing 2-3 negative charges (36). Elimination of the charge on alpha Asp-152 substantially reduces both agonist and antagonist affinities (20). Thus, distinctions between the charged residues at alpha 152, gamma /delta -174/180, and alpha 200 are evident, for the charge at alpha 152 influences the binding of both agonists and antagonists, whereas the charges on gamma 174, delta 180, and alpha 200 selectively influence agonist binding.

Distinguishing the Role of Anionic Charges in Ligand Binding to the nAChR-- Charge neutralization in the vicinity of a ligand recognition site and subunit interface can be expected to exert an influence on ligand selectivity and subunit assembly by multiple mechanisms. Indeed the mRNA encoding the gamma D174N mutation, when co-injected with mRNAs encoding the alpha  and beta  subunits, did not result in expressed receptor on the Xenopus oocyte surface (19); yet we find upon cDNA transfection into mammalian cells, the combination of alpha 2beta (gamma D174N)2 yields an expression level similar to the wild-type alpha 2beta gamma 2. The alpha D152N mutation inserts an additional glycosylation signal in the sequence and increased glycosylation of the alpha -subunit receptor expressed in mammalian cells (20). This mutation yields diminished receptor expression which appears to be a consequence of compromising the initial dimer formation between the alpha  and delta  subunits, and particularly the alpha  and gamma  subunits. Since alpha D152Q and especially alpha D152Y also yield diminished receptor expression when cotransfected with the complement of other subunits, this perturbation of subunit assembly can not be attributed solely to steric hindrance by added oligosaccharide. Assembly of the pentamer can be monitored by sedimentation analysis, but even when assembly occurs, slight alterations in residue apposition at the subunit interface may influence the capacity of the receptor to undergo state changes. Diminished cooperativity seen with receptors of alpha 2beta gamma 2 and alpha 2beta delta 2 compositions with Hill slopes less than unity (28) are indicators of either a compromised state transition or a lack of identity of the two binding sites in these receptors assembled from three distinct subunits.

To underscore the differences in agonist and antagonist selectivity seen between charge neutralization at alpha 152 and at gamma /delta 174/180, we examined these mutations in combination and by substitution of tyrosine for the charges. The influence of the two charges on distinct subunits for both agonist and antagonist binding shows a summation of free energy contributions, presumably reflecting the independent influence of the charges of the receptor on the ligand and, for agonists, the preservation of cooperative state transitions in these particular mutants.

Agonist binding is compromised by substitution of tyrosine for the diacidic amino acid at alpha 152 and gamma 174/delta 180, but antagonists show an enhanced affinity with the substitutions of tyrosine at gamma 174/delta 180. This is of particular interest since d-tubocurarine is a rigid molecule with a fixed distance of 10.5 Å between the two cationic nitrogen centers and distinct hydrophilic and hydrophobic surfaces (37). Hence, the d-tubocurarine, with its multiple aromatic moieties, may actually bind in a different orientation on the receptor where tyrosine has replaced aspartate in the gamma and delta  subunits. For agonists, it appears on basis of proadifen sensitivity that at least part of the affinity reduction seen for carbamylcholine when tyrosine is substituted at gamma 174 and delta 180 arises from the compromised state transition elicited by the agonist.

Mutations in Relation to Multiple States of the Receptor-- Our studies also reveal that elimination of charge of the various anionic residues can affect agonist binding by influencing the degree of desensitization. A multistate scheme where two agonists, L, and one heterotropic ligand, H, bind to the receptor is shown in Scheme 1.


View larger version (15K):
[in this window]
[in a new window]
 
Scheme 1.  

In equilibrium binding for agonists, the observed dissociation constant at equilibrium (Kequil), not only reflects the intrinsic dissociation constants for the activable and desensitized states, KR and KR', respectively, but is influenced by the allosteric constant, M (=R'R'/RR), for the state transitions between the low affinity, activable state and desensitized state (24-30). For simplicity, the channel opening constant, beta /alpha , for the doubly liganded species, LRLR, has been omitted. A heterotropic ligand, such as proadifen, will bind to a distinct site. Its relative affinities for the R'R', and RR receptor states will influence the ratio of high affinity, desensitized to low affinity, activable states of the receptor.

Fractional occupation of the agonist (L), carbamylcholine in our case, can be described in the absence of H by
<A><AC>Y</AC><AC>&cjs1171;</AC></A>=<FR><NU><FR><NU>[L]</NU><DE>K<SUB>R</SUB></DE></FR><FENCE>1+<FR><NU>[L]</NU><DE>K<SUB>R</SUB></DE></FR></FENCE>+M <FR><NU>[L]</NU><DE>K<SUB>R′</SUB></DE></FR><FENCE>1+<FR><NU>[L]</NU><DE>K<SUB>R′</SUB></DE></FR></FENCE></NU><DE><FENCE>1+<FR><NU>[L]</NU><DE>K<SUB>R</SUB></DE></FR></FENCE><SUP>2</SUP>+M<FENCE>1+<FR><NU>[L]</NU><DE>K<SUB>R′</SUB></DE></FR></FENCE><SUP>2</SUP></DE></FR> (Eq. 1)
A heterotropic ligand H, such as proadifen, may be described in terms of altering the allosteric constant M, to yield an apparent constant, M'
M′=M<FENCE><FR><NU>1+<FR><NU>[H]</NU><DE>K<SUB>R′,H</SUB></DE></FR></NU><DE>1+<FR><NU>[H]</NU><DE>K<SUB>R,H</SUB></DE></FR></DE></FR></FENCE><SUP>n</SUP> (Eq. 2)
KR, H and KR', H represent dissociation constants of the heterotropic ligand for the R and R' state of the receptor. Previous studies have shown that proadifen and related ligands preferentially associate with the R' receptor state at a site distinct from the agonist site (25). This shifts the equilibrium toward the high affinity state. Since KR', H <<  KR, H, in the presence of saturating concentrations of heterotropic ligand such as proadifen, Kequil should approach KR'. Table IV shows a tabulation of constants employing Scheme 1. The data reveal differences between the various mutations where an anionic charge is eliminated. The alpha D152Q and gamma D174N/delta D180N mutations yield receptors which have similar shifts to the high affinity state with proadifen and similar concentration dependencies. By contrast, gamma D174Y/delta D180Y and alpha D200Q show smaller shifts induced by proadifen and require larger concentrations of proadifen to affect the shifts.

                              
View this table:
[in this window]
[in a new window]
 
Table IV
Influence of proadifen on carbamylcholine binding to wild-type and mutant acetylcholine receptors
The data are fit to Equations 1 and 2 in the text. M is the allosteric constant. [C]H=0/[C]Hright-arrow infinity is the ratio of carbamylcholine concentrations giving equivalent occupancies in the absence and presence of saturating concentration of proadifen. [H0.5] is the concentration of proadifen producing a half maximal shift in the carbamylcholine concentration dependence (Fig. 4).

When the ligand concentration, [L] is equal to Kequil, <OVL><IT>Y</IT></OVL> is 0.5. Under this condition, Equation 1 can be reduced to
M=<FR><NU>1−<FENCE><FR><NU>K<SUB><UP>equil</UP></SUB></NU><DE>K<SUB>R</SUB></DE></FR></FENCE><SUP>2</SUP></NU><DE><FENCE><FR><NU>K<SUB><UP>equil</UP></SUB></NU><DE>K<SUB>R′</SUB></DE></FR></FENCE><SUP>2</SUP>−1</DE></FR> (Eq. 3)
A previous study estimated KR for carbamylcholine and the wild type receptor to be 6 × 10-5 (21). Using this value, M for wild type receptor is calculated to be 6.6 × 10-5, a value similar to 1.0 × 10-4 derived from mouse receptors in BC3H-1 cells (25). Although we have no data on KR for gamma D174N/delta D180N mutant, a dose-response analysis for acetylcholine with this mutant receptor showed activation to occur at a 140-fold higher concentration (23). Since the difference in concentrations for activation and binding is similar for acetylcholine and carbamylcholine (38), KR for gamma D174N/delta D180N can be approximated to 8.2 × 10-3 M. Then M may be calculated to be 5.6 × 10-5, a value also very close to the constant for wild type receptor. Furthermore, the proadifen concentration dependence of the gamma D174N/delta D180N mutant receptor is superimposable with that of wild type (Fig. 4, panels A and C), suggesting the allosteric constant M in Scheme 1 is similar for this mutant and wild type receptor.

The alpha D200Q mutation shifts the proadifen concentration dependence to higher concentration as well as diminishes the total capacity for desensitization. Hence, alpha Asp-200 appears crucial for not only for receptor channel opening (39), but also for achieving full desensitization. The lack of influence of gamma D174N/delta D180N mutations on the capacity to desensitize shown previously (23) and in these studies suggests that these charges are not required for the state transition associated with desensitization. Hence, the overall dissociation constant measured for agonists at equilibrium is a composite of various contributory equilibria between receptor states. For agonists, at least three states (activable, open channel, and desensitized) are involved and the charge mutations differentially affect the various equilibria.

    FOOTNOTES

* This work was supported in part by United States Public Health Service Grant GM 18360 (to P. T.) and a Rotary International Fellowship and Uehara Memorial Foundation Fellowship (to H. O.).The costs of publication of this article were defrayed in part by the payment of page charges. The article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

Dagger Present address: Department of Psychiatry, Yokohama City University, Yokohama, Japan.

§ To whom correspondence should be addressed: Dept. of Pharmacology 0636, University of California, San Diego, 9500 Gilman Drive, La Jolla, CA 92093-0636. Tel.: 619-534-1366; Fax: 619-534-8248; E-mail: priley{at}ucsd.edu.

1 The abbreviation used is: nAChR, nicotinic acetylcholine receptor.

    REFERENCES
Top
Abstract
Introduction
Procedures
Results
Discussion
References

  1. Unwin, N. (1993) J. Mol. Biol. 229, 1101-1124[CrossRef][Medline] [Order article via Infotrieve]
  2. Karlin, A., and Akabas, M. H. (1995) Neuron 15, 1231-1244[Medline] [Order article via Infotrieve]
  3. Hucho, F., Tsetlin, V. I., and Machold, J. (1996) Eur. J. Biochem. 239, 539-557[Abstract]
  4. Changeux, J-P. (1995) Biochem. Soc. Trans. 23, 195-205[Medline] [Order article via Infotrieve]
  5. Cohen, J. B., Blanton, M. P., Chiara, D. C., Sharp, S. D., and White, B. H. (1992) J. Cell. Biochem. 16E, 217 (abstr.)
  6. Sine, S. M. (1993) Proc. Natl. Acad. Sci. U. S. A. 90, 9436-9440[Abstract]
  7. Czajkowski, C., Kaufmann, C., and Karlin, A. (1993) Proc. Natl. Acad. Sci. U. S. A. 90, 6285-6289[Abstract]
  8. O' Leary, M. E., Filatov, G. N., and White, M. M. (1994) Am. J. Physiol. 266, C648-C653[Abstract/Free Full Text]
  9. Sine, S. M., Kreienkamp, H.-J., Bren, N., Maeda, R., and Taylor, P. (1995) Neuron 15, 205-211[Medline] [Order article via Infotrieve]
  10. Prince, R. J., and Sine, S. M. (1996) J. Biol. Chem. 271, 25770-25777[Abstract/Free Full Text]
  11. Sine, S. M. (1997) J. Biol. Chem. 272, 23521-23527[Abstract/Free Full Text]
  12. Bren, N., and Sine, S. M. (1997) J. Biol. Chem. 272, 30793-30798[Abstract/Free Full Text]
  13. Tsigelny, I., Sugiyama, N., Sine, S. M., and Taylor, P. (1997) Biophys. J. 73, 52-66[Abstract]
  14. Dougherty, D. A. (1996) Science 271, 163-168[Abstract]
  15. Segal, D. M., Padlan, E. A., Cohen, G. H., Rudikoff, S., Potter, M., and Davies, D. R. (1974) Proc. Natl. Acad. Sci. U. S. A. 71, 4295-4302
  16. Sussman, J. L., Harel, M., Frolow, F., Oefner, C., Goldman, A., Toker, L., and Silman, I. (1991) Science 253, 872-879[Medline] [Order article via Infotrieve]
  17. Czajkowski, C., and Karlin, A. (1991) J. Biol. Chem. 266, 22603-22612[Abstract/Free Full Text]
  18. Czajkowski, C., and Karlin, A. (1995) J. Biol. Chem. 270, 3160-3164[Abstract/Free Full Text]
  19. Martin, M., Czajkowski, C., and Karlin, A. (1996) J. Biol. Chem. 271, 13497-13503[Abstract/Free Full Text]
  20. Sugiyama, N., Boyd, A. E., and Taylor, P. (1996) J. Biol. Chem. 271, 26575-26581[Abstract/Free Full Text]
  21. Sine, S. M., and Taylor, P. (1979) J. Biol. Chem. 254, 3315-3325[Abstract]
  22. Sine, S. M., and Taylor, P. (1981) J. Biol. Chem. 256, 6692-6699[Free Full Text]
  23. Martin, M. D., and Karlin, A. (1997) Biochemistry 36, 10742-10750[CrossRef][Medline] [Order article via Infotrieve]
  24. Weber, M., and Changeux, J.-P. (1974) Mol. Pharmacol. 10, 15-34[Abstract]
  25. Sine, S. M., and Taylor, P. (1982) J. Biol. Chem. 257, 8106-8114[Free Full Text]
  26. Taylor, P., Brown, R. D., and Johnson, D. A. (1983) Current Top. Membr. Transp. 18, 407-444
  27. Boyd, N. D, and Cohen, J. B. (1984) Biochemistry 23, 4023-4033[Medline] [Order article via Infotrieve]
  28. Sine, S. M., and Claudio, T. (1991) J. Biol. Chem. 266, 19369-19377[Abstract/Free Full Text]
  29. Sine, S. M., and Claudio, T. (1991) J. Biol. Chem. 266, 13679-13689[Abstract/Free Full Text]
  30. Auerbach, A. (1993) J. Physiol. 461, 339-378[Abstract]
  31. Pressman, D., Grossberg, A. C., Pence, L. H., and Pauling, L. (1946) J. Am. Chem. Soc. 68, 250-255
  32. Radic', Z., Kirchhoff, P. D., Quinn, D. M., McCammon, J. A., and Taylor, P. (1997) J. Biol. Chem. 272, 23265-23277[Abstract/Free Full Text]
  33. Galzi, J.-L., and Changeux, J.-P. (1994) Curr. Opin. Struct. Biol. 4, 554-565
  34. Taylor, P., and Radic', Z. (1994) Annu. Rev. Pharmacol. Toxicol. 34, 281-320[CrossRef][Medline] [Order article via Infotrieve]
  35. Shafferman, A., Ordentlich, A., Barak, D., Stein, D., Ariel, N., and Velan, B. (1996) Biochem. J. 318, 833-840[Medline] [Order article via Infotrieve]
  36. Stauffer, D. A, and Karlin, A (1994) Biochemistry 33, 6840-6849[Medline] [Order article via Infotrieve]
  37. Pauling, P., and Petcher, T. J. (1973) Chem. Biol. Interact. 6, 351-365[CrossRef][Medline] [Order article via Infotrieve]
  38. Sine, S. M., Quiram, P., Papanikolaou, F., Kreienkamp, H.-J., and Taylor, P. (1994) J. Biol. Chem. 269, 8808-8816[Abstract/Free Full Text]
  39. Akk, G., Sine, S., and Auerbach, A. (1996) J. Physiol. 496, 185-196 [Abstract]


Copyright © 1998 by The American Society for Biochemistry and Molecular Biology, Inc.